Page last updated: 2024-10-23

bisoprolol and Obesity

bisoprolol has been researched along with Obesity in 4 studies

Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"The pharmacokinetic data for the three drugs were qualitatively similar."2.68Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. ( Carrupt, PA; Cheymol, G; Levron, JC; Poirier, JM; Snoeck, E; Testa, B; Weissenburger, J, 1997)
"Treatment with amlodipine, candesartan, or indapamide did not significantly affect plasma visfatin levels."1.43Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. ( Piecha, G; Skoczylas, A; Więcek, A, 2016)
" In obese subjects the pharmacokinetic data calculated for sotalol (total clearance (CL), volume of distribution (V beta), half-life of elimination (t1/2), were comparable with those measured in the controls."1.28[Comparison of beta-blocking agents pharmacokinetics in obese and non-obese subjects]. ( Cheymol, G, 1990)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (75.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Skoczylas, A1
Piecha, G1
Więcek, A1
Cheymol, G3
Poirier, JM2
Carrupt, PA1
Testa, B1
Weissenburger, J1
Levron, JC1
Snoeck, E1
Le Jeunne, C1
Ertzbischoff, O1
Engel, F1
Hugues, FC1

Trials

1 trial available for bisoprolol and Obesity

ArticleYear
Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.
    British journal of clinical pharmacology, 1997, Volume: 43, Issue:6

    Topics: Adipose Tissue; Adrenergic beta-Antagonists; Adult; Area Under Curve; Benzopyrans; Binding Sites; Bi

1997

Other Studies

3 other studies available for bisoprolol and Obesity

ArticleYear
Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations.
    Polskie Archiwum Medycyny Wewnetrznej, 2016, Apr-29, Volume: 126, Issue:4

    Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers;

2016
Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers.
    European journal of clinical pharmacology, 1991, Volume: 41, Issue:2

    Topics: Adrenergic beta-Antagonists; Bisoprolol; Cardiovascular System; Female; Humans; Infusions, Intraveno

1991
[Comparison of beta-blocking agents pharmacokinetics in obese and non-obese subjects].
    Bulletin de l'Academie nationale de medecine, 1990, Volume: 174, Issue:7

    Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Female; Humans; Male; Obesity; Propanolamines; Propr

1990